Compare SMID & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | CRDF |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 130.7M |
| IPO Year | 1996 | 2012 |
| Metric | SMID | CRDF |
|---|---|---|
| Price | $35.11 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 6.1K | ★ 705.3K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | 27.37 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $93,446,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.92 | ★ N/A |
| Revenue Growth | 19.03 | ★ 49.61 |
| 52 Week Low | $25.60 | $1.48 |
| 52 Week High | $43.62 | $4.56 |
| Indicator | SMID | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 63.36 | 49.38 |
| Support Level | $35.80 | $1.51 |
| Resistance Level | $36.89 | $1.68 |
| Average True Range (ATR) | 1.32 | 0.09 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 100.00 | 37.52 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.